Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company. It engages in the business of utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in Pasadena, CA.